|
Feb 28
|
Natera Inc (NTRA) Reports Significant Revenue Growth and Improved Gross Margins in Full Year 2023
|
|
Feb 28
|
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Feb 27
|
Natera (NTRA) Management Increased Full Year Guidance
|
|
Feb 27
|
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
|
|
Feb 27
|
Natera secures Medicare coverage for cancer test in 2 new indications
|
|
Feb 17
|
Natera Inc Director Herm Rosenman Sells 93,901 Shares
|
|
Feb 3
|
Insider Sell: CFO Michael Brophy Sells 22,281 Shares of Natera Inc
|
|
Jan 31
|
Insider Sell: CFO Michael Brophy Sells 3,235 Shares of Natera Inc
|
|
Jan 30
|
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
|
|
Jan 29
|
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
|
|
Jan 16
|
Natera Provides Update on Ravgen Trial
|
|
Jan 9
|
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
|
|
Dec 21
|
While Natera (NASDAQ:NTRA) shareholders have made 323% in 5 years, increasing losses might now be front of mind as stock sheds 4.7% this week
|
|
Dec 21
|
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
|
|
Dec 10
|
12 Best Genomics Stocks To Buy Now
|
|
Dec 6
|
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
|
|
Dec 2
|
Insider Sell Alert: Director Rowan Chapman Sells Shares of Natera Inc (NTRA)
|
|
Sep 7
|
Natera Announces Pricing of $250 Million Follow-On Offering
|
|
Sep 6
|
Natera Launches Proposed Follow-On Offering
|
|
Sep 5
|
Natera (NTRA) Reported Solid Quarterly Revenue Despite a Share Price Decline
|